SOLIAIR

タイトルまたは説明

Dear Drug Discovery and Healthcare Investors,   

I would like to introduce to you my Dietary Supplement for Respiratory and Chronic Lung Diseases (Asthma, COPD, Bronchitis etc.)! I believe my product has great potential and a huge market. I would like to explore the possibility of cooperation with you and your company. I am enclosing my presentation and would appreciate your response!    

SOLIAIR™ Product Overview: 
   
SOLIAIR™ is a blend of botanical extracts and a food supplement that contains a unique composition of ingredients, which has reported beneficial impact. SOLIAIR™ can contribute to strengthening the respiratory system and may help patients in chronic respiratory diseases such as Obstructive Lung Disease, Asthma, Bronchitis, COPD (Chronic Obstructive Pulmonary Disease) and other respiratory infections. 

Patients taking SOLIAIR™ reported a decrease in seasonal infections of the respiratory tract. Reducing the incidence of respiratory infections benefit tremendous potential. The SOLIAIR™ food supplement is free of side effects and has no interaction with conventional medication used for treatment of respiratory disorders! 

Each SOLIAIR™ food supplement has been authorized and defined by the Israeli Ministry of Health and according to Pharmacists Regulation. The SOLIAIR™ has a patent pending!  

Solomon Jacob Profile:

At the age of *9, the inventor (Solomon Jacob) was diagnosed with a chronic inflammatory condition of the lungs, possibly COPD (Chronic Obstructive Pulmonary Disease). Solomon realized that COPD is a complex disease and a treatment will have to address several distinct aspects of the disease, possibly by using a complex mixture of plant extracts. 

Knowing the steroids side-effects, Solomon decided to develop a herbal composition and treat himself with it. Solomon found a composition that was very effective and within a short period of time, his lab test returned showing an unusual improvement! 

Market Size Overview:   

COPD (Chronic Obstructive Pulmonary Disease) and Asthma are Common Diseases and Has No Cure Yet! Respiratory Infections are an important factor and increase the mortality of these diseases. It is estimated that **0 million people worldwide suffer from those diseases.

Therapy costs for COPD and its complications totaled in ***6 at $**6.8 billion and are expected to rise to $**9.2 billion by ***1 and to $**2.9 billion by ***1!   

The SOLIAIR™ Company Is Looking for a Partner that:

- 1. Will commercialize the product. 
- 2. Handle all the certification to sell the product. 
- 3. Export the product worldwide. 

SOLIAIR™ Contact Info:

Name: Solomon Jacob  (Inventor & Director)
Company Address: *2 Freud St. Haifa, ****3 Israel 
Phone: ****-(0)**********3 
Cell-Phone: ****-(0)**********3 

- Please Contact SOLIAIR™ Team for More Details! 

Best Regards,
SOLIAIR™ Team 

 
* SOLIAIR™ Company Presentation & Overview (PowerPoint + Video): goo.gl/6faUeJ